نتایج جستجو برای: idarubicin
تعداد نتایج: 767 فیلتر نتایج به سال:
1. COLLINS, E. T. (1897).-Trans. Ophthal. Soc. U.K., Vol. XVII, p. 254. 2. CRUISE, R. R. (1905).-.Trans. Ophthlal. Soc. U.K., Vol. XXV, p. 332. 3. GREGG, N. MCA. (1941).-Trans. Oththal. Soc. Australia, Vol. III, p. 35. 4. MANN, IDA (1937).-tDevelopmental Abniormalities of the Eye. Cambridge University Press, London. Pp. 16 and 98. 5. MAYOU, M. S. (1904).-Trans. Oihthal. Soc. U.K., Vol. XXIV, p....
Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect, prevent and ...
We randomized 66 elderly patients with AML unfit for conventional chemotherapy to receive GCSF from d6 or from d12 after induction-chemotherapy with cytarabine/idarubicin. There was no difference in duration of neutropenia (17 days vs. 19 days, p=0.67) or rate of complications. Delayed treatment can reduce the administration of G-CSF without adverse consequences.
OBJECTIVE To measure the effects of changes in treatment of acute myeloblastic leukaemia that may give better value for money. DESIGN Retrospective analysis of patients' notes to identify items of management costing money; prospective costing of these items. The Medical Research Council acute myeloblastic leukaemia 9 trial was used to identify the amount and distribution of these costs when e...
PURPOSE Recently, a new ABC protein, breast cancer resistance protein (BCRP), was described. But its prognosis is not known in acute myeloid leukemia (AML). In addition, the prognosis of P-glycoprotein (Pgp) and BCRP in patients treated homogeneously by the same anthracycline (daunorubicin, idarubicin, or mitoxantrone) during all of the treatment with aracytine is not known. Therefore, we have ...
We show that treating human trisomic fibroblasts with anthracyclines - aclarubicin, daunorubicin and idarubicin - leads to certain changes in these cells; namely the activation of caspase 3, morphological changes and an increase in the level of intracellular calcium. These results suggest that anthracycline drugs are also able to induce apoptosis in pathological, trisomic cells.
We report an extremely rare case of acute myelomonocytic leukemia (M4) with an MLL-ELL fusion gene lacking the PML-RARα rearrangement that transformed from hypergranular acute promyelocytic leukemia (APL) without showing any karyotypic evolution. The treatment was effective with chemotherapy for M4 and idarubicin plus a cytarabine-based chemotherapy protocol without ATRA.
Intelligent data analysis methods support information extraction from data by exploiting domain’s Background Knowledge. We address several issues regarding definition, use and impact of these methods, and investigate for their acceptance in application domains of medicine and pharmacology by a MEDLINE search. The authors of the paper believe that the basic philosophy of IDA is to be application...
PURPOSE Proteasome inhibition results in cytotoxicity to the leukemia stem cell in vitro. We conducted this phase I study to determine if the proteasome inhibitor bortezomib could be safely added to induction chemotherapy in patients with acute myelogenous leukemia (AML). EXPERIMENTAL DESIGN Bortezomib was given on days 1, 4, 8, and 11 at doses of 0.7, 1.0, 1.3, or 1.5 mg/m(2) with idarubicin...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید